by Elena Iemma | Jan 12, 2026 | Blog, News
In 2025, EpiVax advanced the science of immunogenicity assessment through AI-driven ADA prediction, enhanced in silico tools, expanded in vitro assays and consulting offerings, and new regulatory frameworks supporting biologics and generic peptides. Advancing...
by Elena Iemma | Oct 22, 2025 | Blog
The Power of Tregs: From Sakaguchi’s Nobel Discovery to EpiVax Innovation If you know us, you know we love Tregs. Regulatory T cells (Tregs) are central to how we think about the immune system and nearly everything we do at EpiVax. So, we were thrilled to see this...
by Elena Iemma | Apr 30, 2025 | Blog
Is “Artificial” Intelligence an Option for your ADA? In Case You Missed It: Better ADA Prediction! Guilhem Richard, our CTO, recently presented our new ADA (anti-drug antibody) prediction model to the Antibody Society. The accuracy of the model improved...
by Elena Iemma | Mar 5, 2024 | Events
June 13 & 14, 2024 9:00am – 5:00pm (with receptions to follow!) 350 Eddy St. Providence, RI 02903 Registration is closed The Artificial Intelligence / Human Intelligence & Immunoinformatics Workshop will take place on June 13 and 14th at the South Street...
by Elena Iemma | May 17, 2023 | News
PROVIDENCE, RI, May 17, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is celebrating its 25th birthday by renewing the company’s commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company. In addition,...
